ESTRO 2024 - Abstract Book

S2166

Clinical - Upper GI

ESTRO 2024

The median and 5-year PFS were 10 months and 26%, respectively, and the median and 5-year OS were 17 months and 32%, respectively.

Conclusion:

All patients who underwent definitive RT/CRT for simultaneous pharyngeal and esophageal cancers completed the planned radiation. The treatment suspension periods were acceptable, and adverse events were tolerable. Although this was a limited study with heterogenous patients, the PFS and OS were favorable. This analysis shows that definitive RT/CRT is a safe and effective treatment for patients with simultaneous pharyngeal and esophageal cancers.

Keywords: synchronous cancers, chemoradiation therapy

810

Digital Poster

Additional CRT for superficial esophageal cancer after near- or full-circumferential noncurative ESD